• 1
    Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2008. CA Cancer J Clin. 2008; 58: 71-96.
  • 2
    Colevas AD. Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol. 2006; 24: 2644-2652.
  • 3
    Gibson MK, Li Y, Murphy B, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2005; 23: 3562-3567.
  • 4
    Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol. 2007; 25: 2171-2177.
  • 5
    Bria E, Cuppone F, Ciccarese M, et al. Weekly docetaxel as second line chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials. Cancer Treat Rev. 2006; 32: 583-587.
  • 6
    Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol. 2000; 18: 2354-2362.
  • 7
    Hitt R, Amador ML, Quintela-Fandino M, et al. Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Cancer. 2006; 106: 106-111.
  • 8
    Guardiola E, Peyrade F, Chaigneau L, et al. Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer. Eur J Cancer. 2004; 40: 2071-2076.
  • 9
    Cote JF, Kirzin S, Kramar A, et al. UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan. Clin Cancer Res. 2007; 13: 3269-3275.
  • 10
    Lankisch TO, Schulz C, Zwingers T, et al. Gilbert's syndrome and irinotecan toxicity: combination with UDP-glucuronosyltransferase 1A7 variants increases risk. Cancer Epidemiol Biomarkers Prev. 2008; 17: 695-701.
  • 11
    Murphy BA. Topoisomerases in the treatment of metastatic or recurrent squamous carcinoma of the head and neck. Expert Opin Pharmacother. 2005; 6: 85-92.
  • 12
    Murren JR, Davies M. Irinotecan and taxane combinations for non small-cell lung cancer. Clin Lung Cancer. 2001; 2( suppl 2): S20-S25.
  • 13
    Bleickardt E, Argiris A, Rich R, et al. Phase I dose escalation trial of weekly docetaxel plus irinotecan in patients with advanced cancer. Cancer Biol Ther. 2002; 1: 646-651.
  • 14
    Kyzas PA, Cunha IW, Ioannidis JP. Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a meta-analysis. Clin Cancer Res. 2005; 11: 1434-1440.
  • 15
    Smith BD, Smith GL, Carter D, et al. Prognostic significance of vascular endothelial growth factor protein levels in oral and oropharyngeal squamous cell carcinoma. J Clin Oncol. 2000; 18: 2046-2052.
  • 16
    Gallo O, Masini E, Bianchi B, et al. Prognostic significance of cyclooxygenase-2 pathway and angiogenesis in head and neck squamous cell carcinoma. Hum Pathol. 2002; 33: 708-714.
  • 17
    Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205-216.
  • 18
    Simon R. Optimal 2-stage designs for phase II clinical trials. Control Clin Trials. 1989; 10: 1-10.
  • 19
    Agresti A. Categorical data analysis. New York, NY: John Wiley & Sons; 1990.
  • 20
    Wilcoxon F. Individual comparisons by ranking methods. Biometrics. 1945; 1: 80-83.
  • 21
    Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
  • 22
    Cox DR. Regression models and life tables. J R Stat Soc Series B Stat Methodol. 1972; 23: 187-202.
  • 23
    Mehta CR, Patel NR, Tsiatis AA. Exact significance testing to establish treatment equivalence with ordered categorical data. Biometrics. 1984; 40: 819-825.
  • 24
    Carlini LE, Meropol NJ, Bever J, et al. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res. 2005; 11: 1226-1236.
  • 25
    Mercke Odeberg J, Andrade J, Holmberg K, et al. UGT1A polymorphisms in a Swedish cohort and a human diversity panel, and the relation to bilirubin plasma levels in males and females. Eur J Clin Pharmacol. 2006; 62: 829-837.
  • 26
    Burtness B, Thomas L, Sipples R, et al. Phase II trial of weekly docetaxel/irinotecan combination in advanced pancreatic cancer. Cancer J. 2007; 13: 257-262.
  • 27
    Polyzos A, Kosmas C, Toufexi H, et al. Docetaxel in combination with irinotecan (CPT-11) in platinum-resistant paclitaxel-pretreated ovarian cancer. Anticancer Res. 2005; 25: 3559-3564.
  • 28
    Stathopoulos GP, Tsavdaridis D, Malamos NA, et al. Irinotecan combined with docetaxel in pre-treated metastatic breast cancer patients: a phase II study. Cancer Chemother Pharmacol. 2005; 56: 487-491.
  • 29
    Sym SJ, Chang HM, Kang HJ, et al. A phase II study of irinotecan and docetaxel combination chemotherapy for patients with previously treated metastatic or recurrent advanced gastric cancer. Cancer Chemother Pharmacol. 2008; 63: 1-8.
  • 30
    Wachters FM, Groen HJ, Biesma B, et al. A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb-IV non-small-cell lung cancer who failed first-line treatment. Br J Cancer. 2005; 92: 15-20.
  • 31
    Yamamoto N, Fukuoka M, Negoro SI, et al. Randomised phase II study of docetaxel/cisplatin vs docetaxel/irinotecan in advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group study (WJTOG9803). Br J Cancer. 2004; 90: 87-92.
  • 32
    Lordick F, von Schilling C, Bernhard H, et al. Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer. Br J Cancer. 2003; 89: 630-633.
  • 33
    Kurtz JE, Negrier S, Husseini F, et al. A phase II study of docetaxel-irinotecan combination in advanced pancreatic cancer. Hepatogastroenterology. 2003; 50: 567-570.
  • 34
    Burtness B, Goldwasser MA, Flood W, et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol. 2005; 23: 8646-8654.
  • 35
    Numico G, Merlano M. Second-line treatment with docetaxel after failure of a platinum-based chemotherapy in squamous-cell head and neck cancer. Ann Oncol. 2002; 13: 331-333.
  • 36
    Lim SC, Park SY, Do NY. Correlation of cyclooxygenase-2 pathway and VEGF expression in head and neck squamous cell carcinoma. Oncol Rep. 2003; 10: 1073-1079.
  • 37
    Sweeney CJ, Miller KD, Sissons SE, et al. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res. 2001; 61: 3369-3372.
  • 38
    Hoskins JM, Goldberg RM, Qu P, et al. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst. 2007; 99: 1290-1295.
  • 39
    Handra-Luca A, Hernandez J, Mountzios G, et al. Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma. Clin Cancer Res. 2007; 13: 3855-3859.